In October 2013 and 2014, a study was published in the USA that focused on our attention. It shows how tocotrienols could significantly improve the survival rate after chemotherapy.
An increased effect of chemotherapy drugs WITHOUT additional stress on the organism should be a very desirable effect in oncology. To reduce the rate of recurrences and to be able to dose the chemotherapy drugs lower and therefore place less strain on the organism. The present study clearly documents this effect of delta-tocotrienol.
Experimental animals (mice) were used that quickly develop pancreatic cancer on their own. These were divided into four groups, of which 90% died within 16 weeks in the untreated (placebo) group (10% survival rate). The three other groups received either gemcitabine (100 mg/kg IP twice/week) or delta-tocotrienol (200 mg/kg PO twice/day) or the same.
The results after 16 weeks:
| group | Survival rate |
|---|---|
| untreated (placebo) | 10% |
| Treated only with Gemcitabine | 30% |
| Treated only with delta-tocotrienol | 70% |
| Treated with delta-tocotrienol and Gemcitabine | 90% |
In this study, the tocotrienol even worked better than gemcitabine - which may depend on the concentrations used (see above). The connection is interesting: the survival rate from chemotherapy alone could be increased by additional tocotrienolstripledbecome.
Link to original text (full text available):Vitamin E δ-tocotrienol Prolongs Survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) Transgenic Mouse Model of Pancreatic Cancer.
"The results strongly support further research into delta-tocotrienol alla and in combination with gemcitabine for the prevention and treatment of cancer of the pancreas."
Similar studies already exist for a whole range of chemotherapy drugs and for radiotherapy. More to date in this chapter